赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300485 赛升药业

已收盘 07-03 15:00:00

{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":9.96,"timestamp":1783062213000,"preClose":9.73,"halted":0,"volume":16402805,"delay":0,"changeRate":0.0236,"floatShares":274000000,"shares":482000000,"eps":-0.0431,"marketStatus":"已收盘","change":0.23,"latestTime":"07-03 15:00:00","open":9.75,"high":10.1,"low":9.52,"amount":161000000,"amplitude":0.0596,"askPrice":9.97,"askSize":2561,"bidPrice":9.96,"bidSize":838,"shortable":0,"etf":0,"ttmEps":-0.0431,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.73,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":10.7,"lowLimit":8.76,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.39,"roa":"--","roe":"0.14%","epsLYR":0.03,"committee":-0.458976,"marketValue":4797000000,"turnoverRate":0.0599,"status":0,"floatMarketCap":2727000000},"requestUrl":"/m/hq/s/300485/wiki","defaultTab":"wiki","newsList":[{"id":"2645893830","title":"赛升药业(300485.SZ)收到注射用甲磺酸萘莫司他药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893830","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645893830?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:49","pubTimestamp":1782287368,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布公告，公司于近日收到国家药品监督管理局下发的注射用甲磺酸萘莫司他药品注册受理通知书。据悉，注射用甲磺酸萘莫司他用于改善胰腺炎的急性症状;治疗弥散性血管内凝血综合征(DIC);用于防止有出血性病变或出血倾向的患者血液体外循环时灌流血液的凝固(血液透析和血浆置换)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300485","BK0046","BK0028","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645585340","title":"股市必读：赛升药业（300485）6月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645585340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645585340?lang=zh_cn&edition=full","pubTime":"2026-06-24 01:42","pubTimestamp":1782236530,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，赛升药业报收于9.7元，上涨18.44%，换手率10.95%，成交量29.99万手，成交额2.78亿元。董秘最新回复投资者： 尊敬的董秘您好，补充追问实控人相关传闻事宜：目前市场流传两条相关传闻：1、实控人马骉正在接受证监局立案调查；2、调查涉及实控人体外变相占用上市公司资金。当日关注点交易信息汇总：6月23日主力资金净流入2520.48万元，游资资金净流入1073.5万元，散户资金净流出3593.98万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400001216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645816258","title":"赛升药业：以上均为不实传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2645816258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645816258?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:36","pubTimestamp":1782203767,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，补充追问实控人相关传闻事宜：目前市场流传两条相关传闻：1、实控人马骉正在接受证监局立案调查；2、调查涉及实控人体外变相占用上市公司资金。此前公司仅说明上市公司资金管理合规，并未澄清上述两条传闻的真伪。请问以上市场传闻是否属实？若监管调查已有阶段性结论，烦请同步披露，维护中小投资者知情权，谢谢。赛升药业回复：您好，以上均为不实传闻。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300027984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0239","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645217016","title":"股市必读：赛升药业（300485）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645217016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645217016?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:07","pubTimestamp":1782076033,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，赛升药业报收于8.15元，上涨0.0%，换手率1.63%，成交量4.45万手，成交额3648.35万元。董秘最新回复投资者： 咨询两个问题：一、实控人相关资金规范整改目前进展如何？药品研发及注册申报存在不确定性，敬请投资者注意投资风险。当日关注点交易信息汇总：6月18日主力资金净流出131.74万元，游资资金净流出169.4万元，散户资金净流入301.14万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0239","BK0046","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644703660","title":"赛升药业：公司在研项目K11启动Ⅲ期临床，已完成全部入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2644703660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644703660?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:51","pubTimestamp":1781769086,"startTime":"0","endTime":"0","summary":"公司在研项目及项目情况可关注公司披露的定期报告及临时公告的相关内容。药品研发及注册申报存在不确定性，敬请投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800023798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641710156","title":"赛升药业：截至2026年5月29日，公司股东户数为29850","url":"https://stock-news.laohu8.com/highlight/detail?id=2641710156","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641710156?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:04","pubTimestamp":1780902253,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月08日在投资者关系平台上答复投资者关心的问题。投资者提问：截止6.1日股东户数有多少？赛升药业回复：您好，截至2026年5月29日，公司股东户数为29850。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800013568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904044","title":"赛升药业：目前公司生产经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640904044?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:52","pubTimestamp":1780491130,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司在经营上是否遇到重大困难？自5.6以来贵司以及累计跌幅23%远超创业板指以及板块指数，贵司实控人是否会增持回购提振投资者信心？赛升药业回复：您好，目前公司生产经营正常。未来如有股份回购相关计划，公司将遵照监管要求及时履行信息披露义务，请以公司公告为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300044413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300485","BK0012","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953132","title":"赛升药业(300485)5月20日股东户数2.95万户，较上期减少2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953132","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638953132?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:33","pubTimestamp":1779701630,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年5月20日公司股东户数为2.95万户，较5月8日减少852.0户，减幅为2.81%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至5月20日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年5月8日至2026年5月20日，赛升药业区间跌幅为9.98%，在此期间股东户数减少852.0户，减幅为2.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845319","title":"赛升药业（300485）披露2025年年度权益分派实施公告，5月20日股价下跌3.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845319","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636845319?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:15","pubTimestamp":1779272119,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，赛升药业报收于9.65元，较前一交易日下跌3.88%，最新总市值为46.48亿元。该股当日开盘10.03元，最高10.03元，最低9.6元，成交额达7674.25万元，换手率为2.88%。公司于近日披露《2025年年度权益分派实施公告》。公告显示，北京赛升药业股份有限公司2025年年度权益分派方案已获2026年4月23日召开的年度股东会审议通过。股权登记日为2026年5月26日，除权除息日为2026年5月27日。现金红利由中国结算深圳分公司代派，部分股东由公司自行派发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636153016","title":"股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636153016","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636153016?lang=zh_cn&edition=full","pubTime":"2026-05-18 04:08","pubTimestamp":1779048493,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，赛升药业报收于10.16元，下跌1.74%，换手率1.83%，成交量5.02万手，成交额5137.69万元。来自股本股东变化：截至2026年5月8日，公司股东户数环比下降1.64%，户均持股上升至1.59万股，呈现筹码集中趋势。股本股东变化股东户数变动近日赛升药业披露，截至2026年5月8日公司股东户数为3.03万户，较4月30日减少505.0户，减幅为1.64%。户均持股数量由上期的1.56万股增加至1.59万股，户均持股市值为17.02万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","300485","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635011237","title":"赛升药业：公司在研项目K11预计2026年将完成临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2635011237","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635011237?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:00","pubTimestamp":1778832025,"startTime":"0","endTime":"0","summary":"赛升药业回复：您好，公司在研项目K11预计2026年将完成临床研究，2027年提交上市注册申请。药品研发需经多期临床，周期长、风险高，易受技术、审批、政策等影响，临床研究存在结果不及预期甚至临床研究失败的风险，后续能否获得批准存在不确定性，敬请注意投资风险。有关在研项目具体进展情况可查阅巨潮资讯网公司《2025年年度报告》以及关注后续临时公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500026447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120169","title":"股市必读：赛升药业(300485)股东户数3.08万户，较上期减少12.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633120169?lang=zh_cn&edition=full","pubTime":"2026-05-08 02:07","pubTimestamp":1778177230,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，赛升药业报收于10.78元，下跌1.28%，换手率2.57%，成交量7.04万手，成交额7618.03万元。来自股本股东变化：截至2026年4月30日，赛升药业股东户数环比下降12.37%，户均持股上升至1.56万股。股本股东变化股东户数变动近日赛升药业披露，截至2026年4月30日公司股东户数为3.08万户，较4月10日减少4355.0户，减幅为12.37%。户均持股数量由上期的1.37万股增加至1.56万股，户均持股市值为17.04万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800002067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0028","BK0239","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670944","title":"每周股票复盘：赛升药业（300485）股东户数增8.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670944?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:56","pubTimestamp":1777762573,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，赛升药业报收于10.91元，较上周的11.37元下跌4.05%。本周，赛升药业4月28日盘中最高价报12.14元。股本股东变化股东户数变动截至2026年4月10日，赛升药业股东户数为3.52万户，较3月31日增加2808.0户，增幅8.67%。业绩披露要点财务报告赛升药业2026年一季报显示，一季度公司主营收入9043.89万元，同比下降2.27%；归母净利润466.33万元，同比下降88.33%；扣非净利润1022.51万元，同比上升759.26%；负债率4.76%，投资收益197.19万元，财务费用2.89万元，毛利率68.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631063770","title":"赛升药业：与北京亦庄国际共参与两支基金设立","url":"https://stock-news.laohu8.com/highlight/detail?id=2631063770","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631063770?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:51","pubTimestamp":1777553467,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月29日在投资者关系平台上答复投资者关心的问题。你们共同投资的北京亦庄二期生物医药产业投资基金贵司占股31%，北京亦庄国际占比30%收益如何？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000065930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631338552","title":"赛升药业：公司参与设立基金的投资方向为生命科学及大健康产业相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2631338552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631338552?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:38","pubTimestamp":1777433904,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月29日在投资者关系平台上答复投资者关心的问题。收益情况可查阅巨潮资讯网公司《2025年年度报告》“第八节 财务报告 七、合并财务报表项目注释 10、长期股权投资”及 十、在其他主体中的权益 2、在合营企业或联营企业中的权益”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900037837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630795873","title":"赛升药业(300485.SZ)发布一季度业绩，归母净利润466.33万元，下降88.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630795873","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630795873?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:47","pubTimestamp":1777366064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2026年第一季度报告，该公司营业收入为9043.89万元，同比增长0.00%。归属于上市公司股东的净利润为466.33万元，同比减少88.33%。归属于上市公司股东的扣除非经常性损益的净利润为1022.51万元，同比增长759.26%。基本每股收益为0.0097元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054623","title":"股市必读：赛升药业（300485）4月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629054623?lang=zh_cn&edition=full","pubTime":"2026-04-22 02:38","pubTimestamp":1776796690,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘，赛升药业报收于11.73元，下跌2.33%，换手率3.63%，成交量9.93万手，成交额1.17亿元。来自机构调研要点：公司主营业务毛利率达65.1%，虽因高研发投入导致净利润小幅下降，但主业本身盈利，多个在研项目进入临床阶段。答：尊敬的投资者您好，根据公司2025年年度报告显示，公司2025年主营业务收入为3.98亿元，营业成本为1.39亿元，主营业务毛利率为65.1%。但受研发高投入及对外投资等因素影响，公司整体净利润小幅减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200006378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0239","BK0046","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629525039","title":"赛升药业：公司将全力做好各项经营工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2629525039","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629525039?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:39","pubTimestamp":1776771540,"startTime":"0","endTime":"0","summary":"当前估值水平受多重因素影响，公司将通过扎实经营业绩、加强投资者沟通等方式，推动市场价值合理反映企业基本面。目前公司生产经营各项工作均有序进行，公司将继续坚持踏实做好主业，以长期、稳定、优良的业绩回报股东。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-21/doc-inhvhmhw6111100.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-21/doc-inhvhmhw6111100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300485","BK0046","BK0028","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627191404","title":"赛升药业：截至2026年4月10日，公司股东户数为35194","url":"https://stock-news.laohu8.com/highlight/detail?id=2627191404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627191404?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:57","pubTimestamp":1776157024,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2026年4月10日公司的股东人数是多少?谢谢赛升药业回复：您好，截至2026年4月10日，公司股东户数为35194。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400026811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","BK0046","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419541","title":"赛升药业：公司在研项目K11预计2026年将完成临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419541","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419541?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:51","pubTimestamp":1776156673,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月14日在投资者关系平台上答复投资者关心的问题。同时贵公司是否还有其他创新药项目赛升药业回复：您好，公司在研项目K11预计2026年将完成临床研究，2027年提交上市注册申请。公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3、NeoAB33等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400026629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","300485","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783181263470,"stockEarnings":[{"period":"1week","weight":0.1704},{"period":"1month","weight":0.1448},{"period":"3month","weight":-0.114},{"period":"6month","weight":-0.0553},{"period":"1year","weight":-0.339},{"period":"ytd","weight":-0.0553}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29850人(较上一季度增加1.25%)","perCapita":"9173股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":"　　北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}